Compass Point analyst Laurie Havener downgrades Washington Trust Bancorp (NASDAQ:WASH) from Buy to Neutral and lowers the price target from $60 to $49.
Adial Provides Business Update Following Favorable Comments From US And EU Regulatory Meetings
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of AD04, a genetically targeted, serotonin-3
